Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Hutchison MediPharma Options Program to J&J

publication date: Jan 15, 2009

Hutchison MediPharma Limited and Ortho-McNeil-Janssen Pharmaceuticals, Inc., a division of Johnson & Johnson have formed a collaboration, taking advantage of MediPharma’s work on a novel inflammation/immunology target. MediPharma will continue its discovery and development activities through clinical proof-of-concept, unless OMJPI exercises an option to take over the development. If that happens, OMJPI will have exclusive rights to develop and commercialize the compounds. More details...

Stock Symbols: (AIM: HCM) (NYSE: JNJ)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital